| 5.05 -0.5 (-9.01%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.34 |
1-year : | 8.5 |
| Resists | First : | 6.28 |
Second : | 7.28 |
| Pivot price | 6.35 |
|||
| Supports | First : | 4.68 |
Second : | 3.89 |
| MAs | MA(5) : | 5.72 |
MA(20) : | 6.41 |
| MA(100) : | 4.79  |
MA(250) : | 4.64 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 14.8 |
| RSI | RSI(14): 31.6 |
|||
| 52-week | High : | 8.22 | Low : | 2.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CAPR ] has closed below the lower bollinger band by 10.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 55.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.66 - 5.69 | 5.69 - 5.72 |
| Low: | 4.61 - 4.65 | 4.65 - 4.68 |
| Close: | 5 - 5.06 | 5.06 - 5.1 |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Wed, 17 Apr 2024
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average of $5.44 - MarketBeat
Wed, 17 Apr 2024
Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above 50-Day Moving Average of $5.44 - Defense World
Tue, 16 Apr 2024
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate - Simply Wall St
Sun, 31 Mar 2024
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update - Defense World
Wed, 27 Mar 2024
Is Capricor Therapeutics Inc (CAPR) a Good Buy in the Healthcare Sector? - InvestorsObserver
Mon, 25 Mar 2024
CAPR Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 2.604e+007 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 2,700 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.301e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -88.6 % |
| Operating Margin | -10.7 % |
| Return on Assets (ttm) | -27.7 % |
| Return on Equity (ttm) | -129.7 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 39.43 |
| Sales Per Share | 6.23267e+006 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 27.94 |
| Dividend | 0 |
| Forward Dividend | 3.5e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|